• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

By: Cullinan Therapeutics, Inc. via GlobeNewswire
November 05, 2024 at 07:00 AM EST

CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference, being held in New York on November 18 and 19, 2024.

The fireside chat is scheduled for Tuesday, November 19, 2024, at 1:50 p.m. ET. A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://cullinantherapeutics.com/events-and-presentations/.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.

Contacts:

Investor Relations
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com

Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com


Primary Logo

More News

View More
News headline image
NASA Calls, Plug Answers: A Turning Point for Hydrogen? ↗
Today 13:07 EST
Via MarketBeat
Tickers PLUG
News headline image
Will 2026 Mark a Turnaround for Costco? ↗
Today 12:32 EST
Via MarketBeat
Tickers COST TGT WMT
News headline image
The AI Boom Is Powering an Unexpected Stock Surge—And These 3 Companies Are Winning Big ↗
Today 11:22 EST
Via MarketBeat
Topics Artificial Intelligence
Tickers CIEN COHR LITE
News headline image
The Bulls Are Back—Why Qualcomm Stock Is Gaining Strength Again ↗
Today 10:22 EST
Via MarketBeat
Tickers QCOM
News headline image
Palantir Stock Finds Its Footing—and a Path to Global Growth ↗
Today 8:20 EST
Via MarketBeat
Tickers PLTR

Recent Quotes

View More
Symbol Price Change (%)
AMZN  231.97
-2.45 (-1.05%)
AAPL  285.15
-1.04 (-0.36%)
AMD  216.13
+0.89 (0.41%)
BAC  54.06
+0.88 (1.65%)
GOOG  321.23
+5.21 (1.65%)
META  644.16
-2.94 (-0.46%)
MSFT  481.68
-8.32 (-1.70%)
NVDA  181.03
-0.43 (-0.23%)
ORCL  206.72
+5.62 (2.79%)
TSLA  447.33
+18.09 (4.21%)
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap